跳至主要内容
临床试验/PACTR202112813934276
PACTR202112813934276尚未招募3 期

Delayed Versus Immediate Use Of Zoledronic Acid For Postmenopausal Patients With ER/PR Positive Early Breast Cancer Who Are Using Adjuvant Letrozole

AUH0 个研究点目标入组 50 人开始时间: 2021年12月15日最近更新:
适应症

试验速览

阶段
3 期
状态
尚未招募
发起方
AUH
入组人数
50

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
45 Year(s) 至 64 Year(s)(—)
性别
Female

入选标准

  • 1- Histologic evidence of ER/PR positive breast adenocarcinoma
  • 2- Postmenopausal women.
  • 3- Baseline LS and total hip BMD T-score > -2.0.
  • 4- No prior treatment with denosumab or IV bisphosphonates is allowed.
  • 5- No prior treatment with radiopharmaceuticals.
  • 6- Not pregnant and not nursing.
  • 7- Good dental health.
  • 8- ECOG performance status 0-2.
  • 9- Calculated creatinine clearance >= 30 mL/min.
  • 10- Corrected serum calcium >= 8.0 mg/dL (2.00 mmol/L) and < 11.6 mg/dL (2.90 mmol/L)

排除标准

  • 1- Patients with dental problems.
  • 2- Patients with impaired renal functions
  • 3- Patients with osteopenia, or T- score is below -2.0
  • 4- Patients with history of serious drug hypersensitivity or drug allergy.

研究者

发起方
AUH

相似试验